Soligenix Announces Placement in BioMedWire Editorial on Rare Diseases.

Soligenix Inc. has been featured in a BioMedWire editorial on the challenges of chronic rare diseases in the aging American population. The editorial highlights the urgent need for effective treatments, as over 30 million Americans are affected by rare diseases and most lack FDA-approved treatments. Soligenix's HyBryte treatment is mentioned as a potential solution, with federal policy playing a crucial role in addressing the issue.